Advertisement

Citations to this article

Abstract

Persistently activated or tyrosine-phosphorylated STAT3 (pSTAT3) is found in 50% of lung adenocarcinomas. pSTAT3 is found in primary adenocarcinomas and cell lines harboring somatic-activating mutations in the tyrosine kinase domain of EGFR. Treatment of cell lines with either an EGFR inhibitor or an src kinase inhibitor had no effect on pSTAT3 levels, whereas a pan-JAK inhibitor (P6) blocked activation of STAT3 and inhibited tumorigenesis. Cell lines expressing these persistently activated mutant EGFRs also produced high IL-6 levels, and blockade of the IL-6/gp130/JAK pathway led to a decrease in pSTAT3 levels. In addition, reduction of IL-6 levels by RNA interference led to a decrease in tumorigenesis. Introduction of persistently activated EGFR into immortalized breast epithelial cells led to tumorigenesis, IL-6 expression, and STAT3 activation, all of which could be inhibited with P6 or gp130 blockade. Furthermore, inhibition of EGFR activity in multiple cell lines partially blocked transcription of IL-6 and concurrently decreased production and release of IL-6. Finally, immunohistochemical analysis revealed a positive correlation between pSTAT3 and IL-6 positivity in primary lung adenocarcinomas. Therefore, mutant EGFR could activate the gp130/JAK/STAT3 pathway by means of IL-6 upregulation in primary human lung adenocarcinomas, making this pathway a potential target for cancer treatment.

Authors

Sizhi Paul Gao ... Bayard Clarkson, Jacqueline F. Bromberg

×

Total citations by year

Year: 2015 2014 2013 2012 2011 2010 2009 2008 2007 Total
Citations: 1 41 32 32 29 26 31 15 1 208
Citation information

Citations to this article in year 2009 (31)

Title and authors Publication Year
IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumors
R Rosell, J Bertran-Alamillo, MA Molina, M Taron
Future Oncology 2009
The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
M Hedvat, D Huszar, A Herrmann, JM Gozgit, A Schroeder, A Sheehy, R Buettner, D Proia, CM Kowolik, H Xin, B Armstrong, G Bebernitz, S Weng, L Wang, M Ye, K McEachern, H Chen, D Morosini, K Bell, M Alimzhanov, S Ioannidis, P McCoon, ZA Cao, H Yu, R Jove, M Zinda
Cancer Cell 2009
A component of polysaccharide peptidoglycan complex onLactobacillusinduced an improvement of murine model of inflammatory bowel disease and colitis-associated cancer
S Matsumoto, T Hara, M Nagaoka, A Mike, K Mitsuyama, T Sako, M Yamamoto, S Kado, T Takada
Immunology 2009
Janus Kinase Mutations
RL Levine
Seminars in Oncology 2009
STAT3 tyrosine phosphorylation is critical for interleukin 1 beta and interleukin-6 production in response to lipopolysaccharide and live bacteria
L Samavati, R Rastogi, W Du, M Hüttemann, A Fite, L Franchi
Molecular Immunology 2009
STATs in cancer inflammation and immunity: a leading role for STAT3
H Yu, D Pardoll, R Jove
Nature Reviews Cancer 2009
The VE-cadherin binding domain of fibrinogen induces endothelial barrier permeability and enhances transendothelial migration of malignant breast epithelial cells
A Sahni, MT Arévalo, SK Sahni, PJ Simpson-Haidaris
International Journal of Cancer 2009
Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer
M Pfeiffer, TN Hartmann, M Leick, J Catusse, A Schmitt-Graeff, M Burger
British Journal of Cancer 2009
The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression
YP Luo, H Zhou, J Krueger, C Kaplan, D Liao, D Markowitz, C Liu, T Chen, TH Chuang, R Xiang, RA Reisfeld
Oncogene 2009
Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells
M Walter, S Liang, S Ghosh, PJ Hornsby, R Li
Oncogene 2009
Serum levels of nicotinamide N-methyltransferase in patients with lung cancer
M Tomida, I Mikami, S Takeuchi, H Nishimura, H Akiyama
Journal of Cancer Research and Clinical Oncology 2009
Mina53, a novel c-Myc target gene, is frequently expressed in lung cancers and exerts oncogenic property in NIH/3T3 cells
K Komiya, N Sueoka-Aragane, A Sato, T Hisatomi, T Sakuragi, M Mitsuoka, T Sato, S Hayashi, H Izumi, M Tsuneoka, E Sueoka
Journal of Cancer Research and Clinical Oncology 2009
Activation of Stat3 in renal tumors
C Guo, G Yang, K Khun, X Kong, D Levy, P Lee, J Melamed
American journal of translational research 2009
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway
KS Nguyen, S Kobayashi, DB Costa
Clinical Lung Cancer 2009
IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions
I Airoldi, ED Carlo, C Cocco, E Caci, M Cilli, C Sorrentino, G Sozzi, S Ferrini, S Rosini, G Bertolini, M Truini, F Grossi, LJ Galietta, D Ribatti, V Pistoia
PloS one 2009
Differential baseline and response profile to IFN-gamma gene transduction of IL-6/IL-6 receptor-alpha secretion discriminate primary tumors versus bone marrow metastases of nasopharyngeal carcinomas in culture
AS Chou, HY Wang, HC Chen, MH Tsai, CK Chuang, SK Liao
BMC Cancer 2009
Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells
H Xin, C Zhang, A Herrmann, Y Du, R Figlin, H Yu
Cancer research 2009
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer
S Grivennikov, E Karin, J Terzic, D Mucida, GY Yu, S Vallabhapurapu, J Scheller, S Rose-John, H Cheroutre, L Eckmann, M Karin
Cancer Cell 2009
Stat3 downstream genes serve as biomarkers in human lung carcinomas and chronic obstructive pulmonary disease
P Qu, J Roberts, Y Li, M Albrecht, OW Cummings, JN Eble, H Du, C Yan
Lung cancer (Amsterdam, Netherlands) 2009
Therapeutic targeting of myeloid-derived suppressor cells
S Ugel, F Delpozzo, G Desantis, F Papalini, F Simonato, N Sonda, S Zilio, V Bronte
Current Opinion in Pharmacology 2009
ErbB receptors and signaling pathways in cancer
NE Hynes, G MacDonald
Current Opinion in Cell Biology 2009
gp130-Mediated Stat3 Activation in Enterocytes Regulates Cell Survival and Cell-Cycle Progression during Colitis-Associated Tumorigenesis
J Bollrath, TJ Phesse, VA von Burstin, T Putoczki, M Bennecke, T Bateman, T Nebelsiek, T Lundgren-May, Ö Canli, S Schwitalla, V Matthews, RM Schmid, T Kirchner, MC Arkan, M Ernst, FR Greten
Cancer Cell 2009
Interleukin-6-producing undifferentiated thymic carcinoma with neuroendocrine features
M Suzuki, N Shinagawa, S Oizumi, K Fugo, M Nishimura
Lung Cancer 2009
Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness
A Saidi, M Hagedorn, N Allain, C Verpelli, C Sala, L Bello, A Bikfalvi, S Javerzat
International journal of cancer. Journal international du cancer 2009
Ikappa B kinasebeta/nuclear factor-kappaB activation controls the development of liver metastasis by way of interleukin-6 expression
S Maeda, Y Hikiba, K Sakamoto, H Nakagawa, Y Hirata, Y Hayakawa, A Yanai, K Ogura, M Karin, M Omata
Hepatology 2009

Advertisement
Advertisement